Click Here to return To Results

 

123I-iodobenzamide-SPECT Predicts Dopaminergic Responsiveness in patients with De Dovo Parkinsonism Neurol 42:556-561, Schwarz,J.,et al, 1992 See this aricle in Pubmed Article Abstract We used 123I-iodobenzamide-single photon emission computed tomography (IBZM-SPECT)in a prospectie study to investigate 38 patients with parkinsonism(Hoehn and Yahy stage I to II)not previously treated with dopamimetic drugs.Thirty-four patients only showed symptoms of Parkinson's disease,and four patients showed,in addition,subtle clinical signs of progressive supranuclear palsy or multisystem atrophy.IBZM is a dopamine D2 receptor antagonist detectable by SPECT.We compared IBZM-SPECT results with clinical response to subcutaneous injections of the D1/D2 dopamine receptor agonist apomorphine(38 patients)and long-term dopamimetic therapy (31 patients).IBZM-SPECT results predicted a positive or negative response to apomorphine in 30 of 34 patients(apomorphine repsone in four patients was equivocal)and response to dopamimetic therapy in 27 of 31 patients. Thus,imaging of dopamine D2 receptors using readily available IBZM-SPECT seems to distinguish between L-dopa-responsive(most likely Parkinson's disease of Lewy body type)and L-dopa-unresponsive parkinsonism in patients not previously treated with dopamimetic drugs.

Related Tags

(click to filter results - removes previous filter) apomorphine dopamine receptor dopamine receptor,D2 L-dopa Parkinson disease Parkinson disease,treatment of single photon emission computed tomography

Click Here to return To Results